Brief: Maat Pharma Receives Authorizations For Phase 2b Clinical Trial

Maat Pharma SA

27/03/2023 17:07

March 27 (Reuters) - Maat Pharma Sa  MAAT.PA :
    * RECEIVES TWO CLINICAL TRIAL APPLICATION AUTHORIZATIONS TO
EVALUATE MAAT033 IN TWO THERAPEUTIC INDICATIONS IN EUROPE
    * RECEIVED AUTHORIZATIONS FROM FRENCH AND GERMAN REGULATORY
AUTHORITIES TO INITIATE ITS PHASE 2B CLINICAL TRIAL EVALUATING
MAAT033 IN IMPROVING SURVIVAL IN PATIENTS RECEIVING ALLOGENEIC
HEMATOPOIETIC STEM-CELL TRANSPLANTATION (ALLO-HSCT)
    * RECEIVED REGULATORY AUTHORIZATION IN FRANCE TO INITIATE A
PHASE
1B PILOT STUDY TO EVALUATE MAAT033 IN AMYOTROPHIC LATERAL
SCLEROSIS (ALS)

Source text for Eikon:  ID:nBw6qHFNNa 
Further company coverage:  MAAT.PA 

 (Gdansk newsroom)
 ((gdansk.newsroom@thomsonreuters.com;))